Green Park Bio-Sciences Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 17-07-2024
- Paid Up Capital ₹ 2.50 M
as on 17-07-2024
- Company Age 5 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.95 Cr
as on 17-07-2024
- Revenue 388.10%
(FY 2023)
- Profit 562.31%
(FY 2023)
- Ebitda 1091.80%
(FY 2023)
- Net Worth 47.28%
(FY 2023)
- Total Assets 224.19%
(FY 2023)
About Green Park Bio-Sciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 2.50 M.
The company currently has active open charges totaling ₹2.95 Cr.
Manoj Thammana, Laxmikameshwari Gamini, and Chandramouli Gamini serve as directors at the Company.
- CIN/LLPIN
U24200AP2019PTC111467
- Company No.
111467
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Mar 2019
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Vijayawada
Industry
Company Details
- Location
Chivatam, Andhra Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Green Park Bio-Sciences?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Manoj Thammana  | Director | 20-Feb-2023 | Current |
| Laxmikameshwari Gamini | Director | 14-Feb-2020 | Current |
| Chandramouli Gamini | Director | 20-Feb-2023 | Current |
Financial Performance of Green Park Bio-Sciences.
Green Park Bio-Sciences Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 388.1% increase. The company also saw a substantial improvement in profitability, with a 562.31% increase in profit. The company's net worth Soared by an impressive increase of 47.28%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Green Park Bio-Sciences?
In 2023, Green Park Bio-Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Dots Lifescience Private LimitedActive 16 years 5 daysLaxmikameshwari Gamini and Chandramouli Gamini are mutual person
Genetek Biosciences Private LimitedActive 3 years 8 monthsLaxmikameshwari Gamini and Chandramouli Gamini are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
City Union Bank Limited Creation Date: 26 Jul 2022 | ₹2.95 Cr | Open |
How Many Employees Work at Green Park Bio-Sciences?
Unlock and access historical data on people associated with Green Park Bio-Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Green Park Bio-Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Green Park Bio-Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
